Supporting Information

Sequential administration of virus-like particlebased nanomedicine to elicit enhanced tumor chemotherapy

Chufan Wang, ^a Cheng Xiao, ^a Yurong Chen, ^b Yao Li, ^a Qiang Zhang, ^a

Wenjun Shan, ^c Yulin Li, ^d Shengli Bi, ^e Yunlong Wang, ^d Xiumin Wang*^b

and Lei Ren*af

^a Key Laboratory of Biomedical Engineering of Fujian Province University/Research Center of Biomedical Engineering of Xiamen, Department of Biomaterials, College of Materials, Xiamen University, Xiamen 361005, P. R. China.

^b School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, P. R. China.
 ^c Department of Pharmacology, College of Pharmacy, Army Medical University (Third Military Medical University), Chongqing 400038, P.R. China

^d Henan Bioengineering Research Center, Zhengdong New District, Zhengzhou, China ^e Chinese Center for Disease Control & Prevention, Institute Viral Disease Control & Prevention, Beijing, PR China

^f State Key Lab of Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen 361005, P. R. China.

*Corresponding author

VLPs	DOX-loading(%)	Particle size(nm)	PDI
HBc	-	30.43 ± 1.90	0.228 ± 0.008
RGD-HBc	-	28.79 ± 2.44	$0.218 {\pm} 0.008$
RGD-WHc	-	32.83 ± 2.06	0.225 ± 0.004
RGD-DHBc	-	24.17 ± 3.22	0.232 ± 0.015
DOX@RGD-HBc	9.46 ± 1.11	30.00 ± 2.12	$0.347 {\pm} 0.006$
DOX@RGD-WHc	15.21 ± 2.24	27.72 ± 2.45	$0.339 {\pm} 0.012$
DOX@RGD-DHBc	17.91 ± 1.14	19.83 ± 2.52	$0.362 {\pm} 0.009$

Supplementary Table 1. Characterization of multiple VLPs

 Table S1. Characterization of multiple VLPs.




Figure S1. *In vivo* clearance and tumor accumulation of Cy5.5 labelled RGD-VLPs. (a) Time-course fluorescence intensity from the tumor in live mice. (b) The biodistribution in the major organs (heart, liver, spleen, lung, kidney) and tumor. Major organs (heart, liver, spleen, lung, and kidney) and tumor were collected at 24 h post *i.v.* injection for *ex vivo* imaging. (c) Whole-blood concentrations of Cy5.5 labelled RGD-VLPs in tumor bearing mice.




Figure S2. Humoral immune response to the HBcAg. Balb/C mice (n = 5) were immunized (s.c.) with HBc core proteins (4mg/g). Sera was collected on day 7, 14, 21 and 28 after the first injection on day 0, and the IgG anti-core end point titers that against the HBcAg were determined by ELISA.




Figure S3. Cell viability after 24 h of incubation with various VLPs at increasing concentrations in CT26 cells.




Figure S4. The hemocompatibility of various VLPs *in vitro*. (a, b) Hemolysis assays for RGD-HBc, RGD-WHc, RGD-DHBc VLPs in RBC.




Figure S5. Histological analysis through H&E staining of organ sections of CT26 tumor-bearing mice subjected to various DOX@VLPs sequential treatment. Representative sections (200 X magnification) of major organs and tumors of mice treated with DOX, DOX@RGD-HBc and DOX@VLPs combination. The tissue sections from mice administered with PBS were used as controls.